Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     
  • Bitcoin GBP

    51,641.04
    +305.36 (+0.59%)
     
  • CMC Crypto 200

    1,370.91
    +58.29 (+4.44%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

What Endo International’s Valuation Trend Indicates

What Endo International’s Valuation Trend Indicates

Endo International’s (ENDP) U.S. Branded – Sterile Injectables segment includes branded sterile injectable products such as Vasostrict, Adrenalin, and Aplisol, and generic sterile injectable products such as ephedrine sulphate injection and neostigmine methylsulfate injection. Revenues from this segment increased from $172.17 million in Q1 2017 to $215.85 million in Q1 2018.